grant
Augmented Transgenic TCR-mediated tumor therapy
Organization UNIVERSITY OF WASHINGTONLocation SEATTLE, UNITED STATESPosted 4 Apr 2019Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY2025AffectAntigen PresentationAntigenic DeterminantsAntigensAutoimmuneAutologousAvidityBackBindingBinding DeterminantsBiologicalBiologyCD 200CD200CD28CD28 geneCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCarcinoma CellCell BodyCell Communication and SignalingCell CountCell FunctionCell LineCell NumberCell PhysiologyCell ProcessCell SignalingCell Surface GlycoproteinsCell SurvivalCell ViabilityCellLineCellsCellular FunctionCellular PhysiologyCellular ProcessCheckpoint inhibitorChimera ProteinChimeric ProteinsClass I GenesClinicalClinical TrialsComplexCutaneous Neuroendocrine CarcinomaCutaneous malignancyDataDiseaseDisorderDorsumDose LimitingDown-RegulationEngineered GeneEngineeringEpitopesExhibitsExpression ProfilingFundingFusion ProteinFutureGene ExpressionGene TranscriptionGenerationsGeneticGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic TranscriptionGenomeGrantHLA Class I Histocompatibility Antigen, A-2 Alpha ChainHLA-A Class I Antigen 2HLA-A Histocompatibility Type Antigen 2HLA-A2HLA-A2 AntigenHumanImmune EvasionImmune checkpoint inhibitorImmune mediated therapyImmune responseImmune systemImmunobiologyImmunologic ModelImmunological ModelsImmunologically Directed TherapyImmunomodulationImmunophysiologyImmunotherapyIn SituIn VitroInflammationInflammatoryInflammatory ResponseInfusionInfusion proceduresInterventionIntracellular Communication and SignalingLYT3LaboratoriesLesionLigandsMHC Class IMHC Class I GenesMHC ReceptorMajor Histocompatibility Complex ReceptorMajor Histocompatibility Complex, Class I, A2 AntigenMalignant Epithelial CellMalignant Skin NeoplasmMeasurableMediatingMembrane GlycoproteinsMerkel Cell TumorMerkel CellsMerkel cell cancerMerkel cell carcinomaMerkel's ReceptorMethodologyMiceMice MammalsModelingModern ManMolecular InteractionMurineMusNeuroendocrineNeuroendocrine Carcinoma of the SkinNeuroendocrine SystemNeurosecretory SystemsOncogene ProductsOncogene ProteinsOncoproteinsPD 1PD-1PD1ParticipantPatientsPeptidesPolyomaPolyoma VirusesPolyomavirusPolyomavirus macacaePolyomavirus maccacae 1Post-Translational Modification Protein/Amino Acid BiochemistryPost-Translational ModificationsPost-Translational Protein ModificationPost-Translational Protein ProcessingPosttranslational ModificationsPosttranslational Protein ProcessingProliferatingProtein ModificationProteinsRNA ExpressionRadiationRecombinant DNA TechnologyRefractoryReproducibilityResistanceSV 40SV 40 VirusSV40SV40 VirusSafetySignal TransductionSignal Transduction SystemsSignalingSimian Vacuolating Virus 40Simian virus 40SiteSkin CancerSkin MalignancyStrains Cell LinesSubcellular ProcessSurface GlycoproteinsT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell infiltrationT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-Cell Antigen ReceptorsT-Cell ProliferationT-Cell ReceptorT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT4 CellsT4 LymphocytesT44T8 CellsT8 LymphocytesTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTestingTherapeuticTimeToxic effectToxicitiesTrabecular Skin CarcinomaTranscriptionTumor CellTumor EscapeTumor Immune EscapeUpregulationVacuolating AgentViral Gene ProductsViral Gene ProteinsViral ProteinsVirusactivate T cellsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanti-tumor immune responsebench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practicebiologicbiological signal transductioncancer evasioncancer immune escapecancer immune evasioncancer progressioncell mediated immune responsecheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemotherapycultured cell linecutaneous lesionscytokinedermal lesioneffective therapyeffective treatmentengineered T cellsexperiencegenetically engineeredgenetically engineered T-cellshigh dimensionalityhost responseimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune evasiveimmune modulationimmune regulationimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunogenicimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimprovedin vivoindividual patientinfusionsmalignant skin tumormortalitymouse modelmurine modelneoplasm progressionneoplastic cellneoplastic progressionnext generationperipheral bloodpre-clinical studypreclinical studyprogrammed cell death 1programmed cell death protein 1programmed death 1proliferation capabilityproliferation capacityproliferation potentialproliferative capabilityproliferative capacityproliferative potentialprotein expressionresistantresponsesafety assessmentsingle fraction irradiationsingle fraction radiationskin lesionsle2standard of caresystemic lupus erythematosus susceptibility 2therapeutic T-cell platformthymus derived lymphocytetransgenic T- cellstreatment strategytumortumor evasiontumor immune evasiontumor progressionvacuolating virusvectorvirus protein
Description preview
Project Summary/Abstract
Augmented transgenic T cell receptor therapy for virus positive Merkel cell Carcinoma
Merkel cell carcinoma (MCC) is a highly aggressive and lethal skin cancer. The Merkel cell polyomavirus (MCPyV) is
clonally integrated in ~80% of MCC tumors, which require continuous expression of the MCPyV T-Antigen (T-Ag)
oncoproteins.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click